Eric Benevich - Nov 2, 2022 Form 4 Insider Report for NEUROCRINE BIOSCIENCES INC (NBIX)

Role
Chief Commercial Officer
Signature
/s/ Darin Lippoldt, Attorney-in-Fact
Stock symbol
NBIX
Transactions as of
Nov 2, 2022
Transactions value $
-$1,171,183
Form type
4
Date filed
11/4/2022, 04:56 PM
Previous filing
Oct 19, 2022
Next filing
Nov 10, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NBIX Common Stock Options Exercise $16.7K +400 +2.56% $41.78 16K Nov 2, 2022 Direct
transaction NBIX Common Stock Sale -$50K -400 -2.49% $125.00 15.6K Nov 2, 2022 Direct F1
transaction NBIX Common Stock Options Exercise $375K +8.97K +57.33% $41.78 24.6K Nov 3, 2022 Direct
transaction NBIX Common Stock Sale -$1.12M -8.97K -36.44% $125.02 15.6K Nov 3, 2022 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NBIX Non-Qualified Stock Option Options Exercise -$16.7K -400 -0.71% $41.78 55.8K Nov 2, 2022 Common Stock 400 $41.78 Direct F3
transaction NBIX Non-Qualified Stock Option Options Exercise -$375K -8.97K -16.07% $41.78 46.9K Nov 3, 2022 Common Stock 8.97K $41.78 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The disposition reported in this Form 4 was effected by a broker pursuant to instructions set forth in a Rule 10b5-1 trading plan adopted by the Reporting Person at least 60 days prior to the transaction date in Box 3 above. Additionally, Issuer policy restricts the Reporting Person from amending or otherwise modifying any 10b5-1 trading plan subsequent to adoption of the plan.
F2 Represents a weighted average sales price per share. These shares were sold in multiple transactions at prices ranging from $125.00 to $125.25. The Reporting Person has provided to the issuer, and will provide to any security holder of the issuer or the SEC staff, upon request, information regarding the number of shares sold at each price within the range.
F3 Option granted June 1, 2015 and vested at 25% upon first anniversary (June 1, 2016) and remaining 75% vested in 36 equal monthly installments beginning July 1, 2016.